

# Yasuhiro Fujiwara

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2983752/publications.pdf](https://exaly.com/author-pdf/2983752/publications.pdf)

Version: 2024-02-01

211  
papers

8,280  
citations

65103

42  
h-index

59438

82  
g-index

229  
all docs

229  
docs citations

229  
times ranked

12864  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. <i>Npj Breast Cancer</i> , 2024, 10, .	5.4	0
2	Challenges in Expediting the Development of Oncology Drugs. <i>JCO Oncology Practice</i> , 2023, 19, 216-217.	2.8	3
3	The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 358-361.	4.9	1
4	Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. <i>JCO Oncology Practice</i> , 2021, 17, e416-e425.	2.8	13
5	Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1182-1185.	4.9	4
6	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021, 14, 1015-1025.	3.1	3
7	No-fault compensation schemes for COVID-19 medical products. <i>Lancet, The</i> , 2021, 397, 1707-1708.	12.1	2
8	Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers. <i>BMC Cancer</i> , 2021, 21, 1131.	2.6	3
9	Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 732525.	2.9	2
10	<i>CYP2D6</i> Genotypeâ€“Guided Tamoxifen Dosing in Hormone Receptorâ€“Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 558-566.	15.4	24
11	Rare cancers in Japan: definition, clinical features and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 970-975.	1.4	9
12	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2020, 10, 15535.	3.4	9
13	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.4	8
14	Toward global standardization of conducting fair investigations of allegations of research misconduct. <i>Accountability in Research</i> , 2020, 27, 327-346.	2.5	6
15	MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 596-605.	4.9	21
16	Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDAâ€™s perspective. <i>Journal of Artificial Organs</i> , 2020, 23, 203-206.	1.0	3
17	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. <i>Drug Safety</i> , 2020, 43, 233-242.	3.2	11
18	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 323-329.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. <i>BMC Cancer</i> , 2020, 20, 325.	2.6	11
20	MiR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer. <i>Cancer Science</i> , 2020, 111, 395-405.	4.0	19
21	Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. <i>Oncology Letters</i> , 2020, 20, 336.	1.8	9
22	HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. <i>Oncology Letters</i> , 2020, 20, 38.	1.8	7
23	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. <i>Breast Cancer</i> , 2019, 26, 39-46.	3.0	1
24	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. <i>Translational Oncology</i> , 2019, 12, 1386-1394.	3.8	7
25	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019, 14, 647-656.	3.7	14
26	Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 491-492.	4.9	8
27	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i> , 2019, 109, 84-91.	2.9	21
28	Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Medical Oncology</i> , 2019, 36, 58.	2.7	9
29	Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 812-822.	1.4	18
30	Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 209-216.	2.3	49
31	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	4.0	261
32	A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 803-809.	4.9	3
33	Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. <i>Breast Cancer</i> , 2019, 26, 492-498.	3.0	22
34	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019, 120, 475-480.	6.6	99
35	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. <i>Oncologist</i> , 2019, 24, 266-272.	4.1	4
36	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. <i>Lung Cancer</i> , 2019, 128, 20-25.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40–44 years. <i>Breast Cancer</i> , 2019, 26, 386-396.	3.0	9
38	The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. <i>Internal Medicine</i> , 2019, 58, 1423-1428.	0.7	3
39	Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 334-338.	1.8	10
40	Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 2161-2166.	2.3	28
41	Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. <i>Investigational New Drugs</i> , 2018, 36, 151-155.	2.7	4
42	A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. <i>Anti-Cancer Drugs</i> , 2018, 29, 97-101.	1.4	9
43	TERT promoter hotspot mutations in breast cancer. <i>Breast Cancer</i> , 2018, 25, 292-296.	3.0	30
44	Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. <i>Cancer Science</i> , 2018, 109, 207-214.	4.0	8
45	PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. <i>Cancer Science</i> , 2018, 109, 2558-2566.	4.0	36
46	Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site. <i>BMC Cancer</i> , 2018, 18, 176.	2.6	5
47	Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 275-283.	2.4	2
48	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018, 9, 18540-18547.	2.1	15
49	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1179-1186.	2.4	39
50	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. <i>Cancer Science</i> , 2017, 108, 1520-1529.	4.0	17
51	The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1850-1855.	2.8	5
52	Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2017, 7, 12622.	3.4	23
53	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , 2017, 18, 1512-1522.	10.8	355
54	Visualization of HER2-specific breast cancer intratumoral heterogeneity using <sup>64</sup> Cu-DOTA-trastuzumab PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2146-2147.	6.7	16

#	ARTICLE	IF	CITATIONS
55	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. <i>ESMO Open</i> , 2017, 2, e000150.	4.4	108
56	Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 127-134.	2.4	16
57	The Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in Patients with Ovarian Cancer: a Retrospective Study. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Tj ETQq1 1 0.784314 rgBT /Overlo</i>		
58	Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. <i>BMC Cancer</i> , 2017, 17, 819.	2.6	12
59	Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>Cancer Science</i> , 2017, 108, 987-994.	4.0	20
60	Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. <i>Internal Medicine</i> , 2017, 56, 2879-2882.	0.7	4
61	Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. <i>Scientific Reports</i> , 2016, 6, 23749.	3.4	39
62	Drug induced interstitial lung disease in oncology phase I trials. <i>Cancer Science</i> , 2016, 107, 1830-1836.	4.0	13
63	Evolution of frameworks for expediting access to new drugs in Japan. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 293-294.	61.5	33
64	Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. <i>Oncologist</i> , 2016, 21, 508-513.	4.1	32
65	Novel combination of serum microRNA for detecting breast cancer in the early stage. <i>Cancer Science</i> , 2016, 107, 326-334.	4.0	289
66	Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 745-752.	2.4	10
67	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. <i>Molecular Cancer</i> , 2016, 15, 73.	20.2	48
68	The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. <i>Breast Cancer</i> , 2016, 23, 797-806.	3.0	2
69	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 447-455.	2.3	152
70	Molecular imaging using PET for breast cancer. <i>Breast Cancer</i> , 2016, 23, 24-32.	3.0	28
71	Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. <i>Breast Cancer</i> , 2016, 23, 624-632.	3.0	13
72	The expression and clinical significance of ribophorin II (RPN2) in human breast cancer. <i>Pathology International</i> , 2015, 65, 301-308.	1.4	24

#	ARTICLE	IF	CITATIONS
73	A phase I study of farletuzumab, a humanized anti-folate receptor $\hat{\pm}$ monoclonal antibody, in patients with solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 332-340.	2.7	24
74	Japanese universal health care faces a crisis in cancer treatment. <i>Lancet Oncology</i> , The, 2015, 16, 251-252.	10.8	18
75	Back with a Vengeance: Microvascular Tumor Embolism. <i>American Journal of Medicine</i> , 2015, 128, 834-836.	1.4	1
76	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 12-18.	1.4	27
77	$^{64}\text{Cu}$ -DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. <i>EJNMMI Research</i> , 2015, 5, 8.	2.6	85
78	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. <i>Breast Cancer</i> , 2015, 22, 141-152.	3.0	34
79	Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 82-89.	2.3	13
80	Nucleostemin expression in invasive breast cancer. <i>BMC Cancer</i> , 2014, 14, 215.	2.6	22
81	Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/III breast cancer without HER2 overexpression. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 401-409.	2.5	63
82	Physicians's knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. <i>Breast Cancer</i> , 2013, 20, 230-240.	3.0	70
83	Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. <i>Breast Cancer</i> , 2013, 20, 145-151.	3.0	17
84	A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1369-1374.	2.4	8
85	Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. <i>Breast</i> , 2013, 22, 263-267.	2.3	24
86	A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2013, 18, 621-628.	2.3	19
87	A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. <i>International Journal of Clinical Oncology</i> , 2013, 18, 590-597.	2.3	7
88	Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 941-950.	2.5	25
89	Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 132-138.	2.3	104
90	$^{64}\text{Cu}$ -DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1869-1875.	6.1	243

#	ARTICLE	IF	CITATIONS
91	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. <i>Molecular and Clinical Oncology</i> , 2013, 1, 995-1001.	1.1	10
92	Quantitative assessment of appearance changes and related distress in cancer patients. <i>Psycho-Oncology</i> , 2013, 22, 2140-2147.	2.5	53
93	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. <i>Clinical Cancer Research</i> , 2012, 18, 4841-4849.	7.2	126
94	Significant Association between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2012, 35, 717-724.	1.5	29
95	The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 319-324.	1.8	8
96	Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. <i>Cancer Science</i> , 2012, 103, 1665-1671.	4.0	90
97	Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 391-397.	2.4	15
98	Immunohistochemical Profile for Unknown Primary Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e31181.	2.5	25
99	Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1249-1257.	2.6	16
100	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 793-805.	2.5	277
101	Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 49-56.	2.6	9
102	The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics. <i>Breast</i> , 2012, 21, 289-295.	2.3	99
103	A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2012, 125, 307-311.	1.4	27
104	Outcomes of Japanese breast cancer patients treated with preoperative and postoperative anastrozole or tamoxifen. <i>Cancer Science</i> , 2012, 103, 491-496.	4.0	2
105	Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 457-465.	2.4	37
106	Breast Cancer Stem Cell: Translating to the Clinic. , 2012, , 249-257.		1
107	Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal. <i>PLoS ONE</i> , 2012, 7, e44393.	2.5	3
108	Genomics, Health Care, and Society. <i>New England Journal of Medicine</i> , 2011, 365, 2339-2339.	30.1	4

#	ARTICLE	IF	CITATIONS
109	Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 394-398.	1.1	14
110	Atypical tumor-stromal fibroblasts in invasive ductal carcinomas of the breast treated with neoadjuvant therapy. <i>Human Pathology</i> , 2011, 42, 998-1006.	2.3	6
111	Do investigators show selection biases when enrolling patients in phase I oncology registration trials?. <i>Journal of Geriatric Oncology</i> , 2011, 2, 25-30.	1.1	1
112	Efficacy of taxane regimens in patients with metastatic angiosarcoma. <i>European Journal of Dermatology</i> , 2011, 21, 539-545.	0.6	26
113	Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor- $\beta$ and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 2841-2850.	2.0	27
114	The notorious "drug lag" for oncology drugs in Japan. <i>Investigational New Drugs</i> , 2011, 29, 706-712.	2.7	46
115	First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 829-838.	2.5	43
116	Second-line chemotherapy in patients with primary unknown cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1185-1191.	2.6	3
117	Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 337-342.	2.4	17
118	A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. <i>Medical Oncology</i> , 2011, 28, 434-440.	2.7	2
119	Prognostic Factors in Young Japanese Women with Breast Cancer: Prognostic Value of Age at Diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 180-189.	1.4	20
120	De-identification Procedure and Sample Quality of the Post-clinical Test Samples at the Bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 295-298.	1.4	3
121	Reply to V. Fusco et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e523-e524.	15.4	7
122	Reply to M.S. Aapro. <i>Journal of Clinical Oncology</i> , 2011, 29, e421-e423.	15.4	1
123	Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. <i>Journal of Orthopaedic Science</i> , 2010, 15, 654-660.	1.2	22
124	Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 127-136.	2.5	85
125	Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. <i>Cancer</i> , 2010, 116, 302-308.	4.1	118
126	Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2010, 101, 222-227.	1.7	17



#	ARTICLE	IF	CITATIONS
127	Feasibility and usefulness of the "Distress Screening Program in Ambulatory Care"™ in clinical oncology practice. <i>Psycho-Oncology</i> , 2010, 19, 718-725.	2.5	59
128	Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 248-250.	1.3	0
129	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5132-5139.	15.4	1,414
130	Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy. <i>Modern Pathology</i> , 2010, 23, 581-592.	5.6	11
131	Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , 2010, 3, 36-40.	0.4	0
132	Weekly Administration of Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian or Peritoneal Cancers With Poor Performance Status. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , 2010, 3, 47-51.	0.4	1
133	Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 699-706.	1.4	9
134	Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 484-490.	1.4	15
135	Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 443-448.	1.4	12
136	Factors That Affect the Duration of the Interval Between the Completion of Palliative Chemotherapy and Death. <i>Oncologist</i> , 2009, 14, 752-759.	4.1	42
137	Relapse with Malignant Transformation After Chemotherapy for Primary Mediastinal Seminoma: Case Report. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 456-459.	1.4	5
138	21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. <i>Breast</i> , 2009, 18, 171-174.	2.3	48
139	Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 551-557.	2.6	15
140	Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2009, 14, 48-52.	2.3	38
141	Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. <i>Journal of Neuro-Oncology</i> , 2009, 93, 205-212.	3.0	127
142	Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 307-313.	2.5	19
143	Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. <i>Medical Oncology</i> , 2009, 26, 344-349.	2.7	28
144	Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer. <i>World Journal of Surgery</i> , 2009, 33, 44-51.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS. <i>Journal of Proteome Research</i> , 2009, 8, 457-462.	3.8	26
146	Immunohistochemical profiles of brain metastases from breast cancer. <i>Journal of Neuro-Oncology</i> , 2008, 90, 223-228.	3.0	36
147	Personalized systemic treatment for breast cancer patients: is it a reality?. <i>Breast Cancer</i> , 2008, 15, 141-144.	3.0	1
148	Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. <i>International Journal of Clinical Oncology</i> , 2008, 13, 555-558.	2.3	7
149	Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 389-395.	2.6	5
150	Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1199-1206.	2.6	12
151	Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. <i>Cancer Science</i> , 2008, 99, 1237-1242.	4.0	78
152	N-glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. <i>Cancer Science</i> , 2008, 99, 1611-1617.	4.0	76
153	Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 567-570.	1.4	9
154	Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 214-221.	1.4	11
155	Clinical Efficacy of S-1 in Pretreated Metastatic Breast Cancer Patients. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 172-175.	1.4	8
156	Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 777-785.	1.4	37
157	Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. <i>Oncology Reports</i> , 2008, , .	2.6	8
158	Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 1-8.	1.4	19
159	Development and validation of diagnostic prediction model for solitary pulmonary nodules. <i>Respirology</i> , 2007, 12, 856-862.	2.9	50
160	Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. <i>Breast</i> , 2007, 16, 482-488.	2.3	25
161	Weekly Paclitaxel and Carboplatin against Advanced Transitional Cell Cancer after Failure of a Platinum-Based Regimen. <i>European Urology</i> , 2007, 52, 1115-1122.	5.0	40
162	Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 313-318.	2.5	4

#	ARTICLE	IF	CITATIONS
163	Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. <i>Medical Oncology</i> , 2007, 24, 425-430.	2.7	15
164	The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 6-8.	1.3	4
165	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. <i>Pathology Research and Practice</i> , 2006, 202, 705-712.	2.3	45
166	Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 9-17.	2.5	136
167	Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 635-642.	2.6	12
168	Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. <i>International Journal of Clinical Oncology</i> , 2006, 11, 421-425.	2.3	21
169	The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 412-416.	1.4	50
170	Diagnosis of Complete Response to Neoadjuvant Chemotherapy Using Diagnostic Imaging in Primary Breast Cancer Patients. <i>Breast Journal</i> , 2005, 11, 311-316.	1.1	17
171	A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. <i>Cancer</i> , 2005, 104, 1204-1212.	4.1	10
172	Translational studies for target-based drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 90-93.	2.4	12
173	Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. <i>International Journal of Clinical Oncology</i> , 2005, 10, 272-275.	2.3	2
174	The Role of DNA-Microarray in Translational Cancer Research. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 201-216.	0.3	1
175	Re: Insulinlike growth factor 1 receptor: predictive factor in breast cancer patients treated with trastuzumab?. <i>Human Pathology</i> , 2005, 36, 449-449.	2.3	1
176	Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. <i>Human Pathology</i> , 2004, 35, 1537-1542.	2.3	105
177	Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 145-155.	4.5	28
178	Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 42-46.	2.4	31
179	Increased expression of theMRP5 gene is associated with exposure to platinum drugs in lung cancer. <i>International Journal of Cancer</i> , 2000, 86, 95-100.	5.4	39
180	Glutathione S-transferase- $\gamma$ gene expression and platinum drug exposure in human lung cancer. <i>Cancer Letters</i> , 2000, 156, 93-99.	7.3	28

#	ARTICLE	IF	CITATIONS
181	Differential Expression of DNA Topoisomerase II <sup>±</sup> and II <sup>2</sup> Genes between Small Cell and Non-small Cell Lung Cancer. Japanese Journal of Cancer Research, 1998, 89, 855-861.	1.6	12
182	ZK1, a Novel KrÄ¼ppel-Type Zinc Finger Gene, Is Induced Following Exposure to Ionizing Radiation and Enhances Apoptotic Cell Death on Hematopoietic Cells. Biochemical and Biophysical Research Communications, 1998, 249, 595-600.	2.2	13
183	The Role of Glucuronidation in 7-Ethyl-10-hydroxycamptothecin Resistance in vitro. Japanese Journal of Cancer Research, 1997, 88, 1211-1217.	1.6	49
184	Enhancement of Tumor Radio-response by Irinotecan in Human Lung Tumor Xenografts. Japanese Journal of Cancer Research, 1997, 88, 218-223.	1.6	73
185	Overcoming CPT-11 resistance by using a biscochlorine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. International Journal of Cancer, 1997, 72, 295-300.	5.4	11
186	No Alteration in DNA Topoisomerase I Gene Related to CPT-11 Resistance in Human Lung Cancer. Japanese Journal of Cancer Research, 1996, 87, 1280-1287.	1.6	36
187	Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer. Japanese Journal of Cancer Research, 1995, 86, 490-500.	1.6	7
188	High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. Biomedical Applications, 1995, 670, 309-316.	1.7	49
189	Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. Journal of Cancer Research and Clinical Oncology, 1995, 121, 729-738.	2.6	27
190	Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection. Japanese Journal of Cancer Research, 1994, 85, 1240-1246.	1.6	55
191	CIS-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. International Journal of Cancer, 1993, 55, 616-622.	5.4	22
192	The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non-small Cell Lung Cancer Cell Line (PC-14) and Its Cisplatin-resistant Subline (PC-14/CDDP). Japanese Journal of Cancer Research, 1993, 84, 83-92.	1.6	45
193	Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochemical and Biophysical Research Communications, 1992, 188, 571-577.	2.2	97
194	In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines. Cancer Chemotherapy and Pharmacology, 1992, 30, 417-422.	2.4	10
195	Alteration of Type II Regulatory Subunit of cAMP-dependent Protein Kinase in Human Cisplatin-resistant Cells as a Basis of Collateral Sensitivity to 8-Chloro-cAMP. Japanese Journal of Cancer Research, 1992, 83, 754-760.	1.6	9
196	Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. Journal of Cancer Research and Clinical Oncology, 1992, 119, 28-34.	2.6	21
197	Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum(II). International Journal of Cancer, 1992, 50, 438-442.	5.4	14
198	Reversal of Cisplatin Resistance with Amphotericin B in a Non-small Cell Lung Cancer Cell Line. Japanese Journal of Cancer Research, 1991, 82, 747-751.	1.6	33

#	ARTICLE	IF	CITATIONS
199	Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-o-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. <i>International Journal of Cancer</i> , 1991, 48, 931-937.	5.4	17
200	Determinants of Drug Response in a Cisplatin-resistant Human Lung Cancer Cell Line. <i>Japanese Journal of Cancer Research</i> , 1990, 81, 527-535.	1.6	73
201	Detection of Proteins that Recognize Platinum-modified DNA Using Gel Mobility Shift Assay. <i>Japanese Journal of Cancer Research</i> , 1990, 81, 1210-1213.	1.6	8
202	Characterization of an etoposide-resistant human small-cell lung cancer cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 313-317.	2.4	64
203	Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 243-246.	2.4	88
204	Inhibition of Colony Formation of Drug-resistant Human Tumor Cell Lines by Combinations of Interleukin-2-activated Killer Cells and Antitumor Drugs. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 265-270.	1.6	8
205	Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 783-786.	1.6	7
206	Clinical features and the result of treatment for brain metastases in advanced non-small cell lung cancer.. <i>Japanese Journal of Lung Cancer</i> , 1989, 29, 649-655.	0.1	0
207	In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 22, 246-250.	2.4	70
208	LEVELS OF GLUTATHIONES TRANSFERASE mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN. <i>Japanese Journal of Cancer Research</i> , 1988, 79, 301-304.	1.6	79
209	In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. <i>Investigational New Drugs</i> , 1987, 5, 353-9.	2.7	7
210	Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). <i>Journal of Cancer Research and Clinical Oncology</i> , 1987, 113, 563-566.	2.6	32
211	Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. <i>Breast Cancer</i> , 0, , .	3.0	0